|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
35,422 |
$2,082,813.60 |
7.17% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
17,843 |
$2,014,296.27 |
6.93% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
8,893 |
$2,010,707.30 |
6.92% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,100 |
$1,935,108.00 |
6.66% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
9,520 |
$1,908,760.00 |
6.57% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
5,759 |
$1,094,613.13 |
3.77% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
73,989 |
$1,074,320.28 |
3.70% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
39,951 |
$1,070,686.80 |
3.68% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,413 |
$1,054,917.54 |
3.63% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,426 |
$990,223.52 |
3.41% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,846 |
$984,488.32 |
3.39% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,416 |
$985,586.40 |
3.39% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,223 |
$972,940.41 |
3.35% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
4,819 |
$966,450.45 |
3.33% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,630 |
$936,092.70 |
3.22% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,347 |
$677,432.80 |
2.33% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
6,843 |
$661,991.82 |
2.28% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,279 |
$481,571.15 |
1.66% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,657 |
$477,238.50 |
1.64% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
865 |
$439,817.90 |
1.51% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,127 |
$393,069.60 |
1.35% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,449 |
$386,061.65 |
1.33% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,630 |
$345,003.40 |
1.19% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,318 |
$342,119.70 |
1.18% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,005 |
$342,342.00 |
1.18% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,380 |
$282,741.20 |
0.97% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,533 |
$257,909.00 |
0.89% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,925 |
$245,375.50 |
0.84% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,100 |
$204,459.00 |
0.70% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,238 |
$204,641.60 |
0.70% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,459 |
$198,558.58 |
0.68% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,049 |
$193,427.19 |
0.67% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,611 |
$193,005.12 |
0.66% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
766 |
$173,782.42 |
0.60% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,650 |
$174,157.50 |
0.60% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,583 |
$170,763.02 |
0.59% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
12,984 |
$166,454.88 |
0.57% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
2,836 |
$157,681.60 |
0.54% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,646 |
$155,234.26 |
0.53% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,250 |
$153,037.50 |
0.53% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,591 |
$150,472.53 |
0.52% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
551 |
$152,042.94 |
0.52% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,663 |
$147,624.51 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,618 |
$144,908.08 |
0.50% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
456 |
$141,624.48 |
0.49% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,872 |
$140,081.76 |
0.48% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,776 |
$139,605.04 |
0.48% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,186 |
$137,576.64 |
0.47% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,633 |
$133,783.75 |
0.46% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,012 |
$127,721.76 |
0.44% |
| US Dollar |
$USD |
|
Other |
80,894 |
$80,894.22 |
0.28% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|